OKYO Pharma Ltd, a clinical-stage biopharmaceutical company listed on the NASDAQ Capital Market under the symbol OKYO, operates in the healthcare industry with a focus on developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. The company is based in Guernsey and has undergone several name changes and rebranding efforts since its incorporation in 2
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | VKTX | Viking Therapeutics, Inc. | - | - | - | - |
| 2 | BOLT | Bolt Biotherapeutics, Inc. | - | - | - | - |
| 3 | GERN | Geron Corp | - | - | - | 119.55 Mn |
| 4 | VTVT | vTv Therapeutics Inc. | - | - | - | - |
| 5 | DYAI | Dyadic International Inc | - | - | - | - |
| 6 | VIR | Vir Biotechnology, Inc. | - | - | - | - |
| 7 | NAMS | NewAmsterdam Pharma Co N.V. | - | - | - | 57.27 Mn |
| 8 | RLYB | Rallybio Corp | - | - | - | - |